Literature DB >> 24528237

The Concise Guide to PHARMACOLOGY 2013/14: overview.

Stephen P H Alexander1, Helen E Benson, Elena Faccenda, Adam J Pawson, Joanna L Sharman, John C McGrath, William A Catterall, Michael Spedding, John A Peters, Anthony J Harmar, N Abul-Hasn, C M Anderson, C M H Anderson, M S Araiksinen, M Arita, E Arthofer, E L Barker, C Barratt, N M Barnes, R Bathgate, P M Beart, D Belelli, A J Bennett, N J M Birdsall, D Boison, T I Bonner, L Brailsford, S Bröer, P Brown, G Calo, W G Carter, W A Catterall, S L F Chan, M V Chao, N Chiang, A Christopoulos, J J Chun, J Cidlowski, D E Clapham, S Cockcroft, M A Connor, H M Cox, A Cuthbert, F M Dautzenberg, A P Davenport, P A Dawson, G Dent, J P Dijksterhuis, C T Dollery, A C Dolphin, M Donowitz, M L Dubocovich, L Eiden, K Eidne, B A Evans, D Fabbro, C Fahlke, R Farndale, G A Fitzgerald, T M Fong, C J Fowler, J R Fry, C D Funk, A H Futerman, V Ganapathy, B Gaisnier, M A Gershengorn, A Goldin, I D Goldman, A L Gundlach, B Hagenbuch, T G Hales, J R Hammond, M Hamon, J C Hancox, R L Hauger, D L Hay, A J Hobbs, M D Hollenberg, N D Holliday, D Hoyer, N A Hynes, K-I Inui, S Ishii, K A Jacobson, G E Jarvis, M F Jarvis, R Jensen, C E Jones, R L Jones, K Kaibuchi, Y Kanai, C Kennedy, I D Kerr, A A Khan, M J Klienz, J P Kukkonen, J Y Lapoint, R Leurs, E Lingueglia, J Lippiat, S J Lolait, S C R Lummis, J W Lynch, D MacEwan, J J Maguire, I L Marshall, J M May, C A McArdle, J C McGrath, M C Michel, N S Millar, L J Miller, V Mitolo, P N Monk, P K Moore, A J Moorhouse, B Mouillac, P M Murphy, R R Neubig, J Neumaier, B Niesler, A Obaidat, S Offermanns, E Ohlstein, M A Panaro, S Parsons, R G Pwrtwee, J Petersen, J-P Pin, D R Poyner, S Prigent, E R Prossnitz, N J Pyne, S Pyne, J G Quigley, R Ramachandran, E L Richelson, R E Roberts, R Roskoski, R A Ross, M Roth, G Rudnick, R M Ryan, S I Said, L Schild, G J Sanger, K Scholich, A Schousboe, G Schulte, S Schulz, C N Serhan, P M Sexton, D R Sibley, J M Siegel, G Singh, R Sitsapesan, T G Smart, D M Smith, T Soga, A Stahl, G Stewart, L A Stoddart, R J Summers, B Thorens, D T Thwaites, L Toll, J R Traynor, T B Usdin, R J Vandenberg, C Villalon, M Vore, S A Waldman, D T Ward, G B Willars, S J Wonnacott, E Wright, R D Ye, A Yonezawa, M Zimmermann.   

Abstract

The Concise Guide to PHARMACOLOGY 2013/14 provides concise overviews of the key properties of over 2000 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties from the IUPHAR database. The full contents can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.12444/full. This compilation of the major pharmacological targets is divided into seven areas of focus: G protein-coupled receptors, ligand-gated ion channels, ion channels, catalytic receptors, nuclear hormone receptors, transporters and enzymes. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. A new landscape format has easy to use tables comparing related targets. It is a condensed version of material contemporary to late 2013, which is presented in greater detail and constantly updated on the website www.guidetopharmacology.org, superseding data presented in previous Guides to Receptors & Channels. It is produced in conjunction with NC-IUPHAR and provides the official IUPHAR classification and nomenclature for human drug targets, where appropriate. It consolidates information previously curated and displayed separately in IUPHAR-DB and GRAC and provides a permanent, citable, point-in-time record that will survive database updates.
Copyright © 2013 The British Pharmacological Society.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24528237      PMCID： PMC3892286          DOI： 10.1111/bph.12444

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


1449 OVERVIEW 1454 Adiponectin receptors 1455 Fatty acid binding proteins 1457 Sigma receptors 1459 G PROTEIN-COUPLED RECEPTORS 1462 Orphan GPCRs 1471 5-Hydroxytryptamine receptors 1474 Acetylcholine receptors (muscarinic) 1476 Adenosine receptors 1478 Adhesion Class GPCRs 1480 Adrenoceptors 1484 Angiotensin receptors 1485 Apelin receptor 1486 Bile acid receptor 1487 Bombesin receptors 1488 Bradykinin receptors 1489 Calcitonin receptors 1491 Calcium-sensing receptors 1492 Cannabinoid receptors 1494 Chemerin receptor 1495 Chemokine receptors 1500 Cholecystokinin receptors 1501 Complement peptide receptors 1502 Corticotropin-releasing factor receptors 1503 Dopamine receptors 1505 Endothelin receptors 1506 Estrogen (G protein-coupled) receptor 1507 Formylpeptide receptors 1508 Free fatty acid receptors 1510 Frizzled Class GPCRs 1511 GABAB receptors 1513 Galanin receptors 1514 Ghrelin receptor 1515 Glucagon receptor family 1517 Glycoprotein hormone receptors 1518 Gonadotrophin-releasing hormone receptors 1519 GPR18, GPR55 and GPR119 1520 Histamine receptors 1521 Hydroxycarboxylic acid receptors 1522 Kisspeptin receptors 1523 Leukotriene, lipoxin and oxoeicosanoid receptors 1525 Lysophospholipid (LPA) receptors 1526 Lysophospholipid (S1P) receptors 1527 Melanin-concentrating hormone receptors 1528 Melanocortin receptors 1529 Melatonin receptors 1530 Metabotropic glutamate receptors 1532 Motilin receptor 1533 Neuromedin U receptors 1534 Neuropeptide FF/neuropeptide AF receptors 1535 Neuropeptide S receptor 1536 Neuropeptide W/neuropeptide B receptors 1537 Neuropeptide Y receptors 1538 Neurotensin receptors 1539 Opioid receptors 1541 Orexin receptors 1542 Oxoglutarate receptor 1543 P2Y receptors 1545 Parathyroid hormone receptors 1546 Peptide P518 receptor 1547 Platelet-activating factor receptor 1548 Prokineticin receptors 1549 Prolactin-releasing peptide receptor 1550 Prostanoid receptors 1552 Proteinase-activated receptors 1553 Relaxin family peptide receptors 1555 Somatostatin receptors 1556 Succinate receptor 1557 Tachykinin receptors 1558 Thyrotropin-releasing hormone receptors 1559 Trace amine receptor 1560 Urotensin receptor 1561 Vasopressin and oxytocin receptors 1562 VIP and PACAP receptors 1582 LIGAND-GATED ION CHANNELS 1584 5-HT3 receptors 1586 GABAA receptors 1590 Glycine receptors 1592 Ionotropic glutamate receptors 1597 Nicotinic acetylcholine receptors 1601 P2X receptors 1603 ZAC 1607 ION CHANNELS 1609 Acid-sensing (proton-gated) ion channels (ASICs) 1611 Aquaporins 1612 CatSper and Two-Pore channels 1613 Chloride channels 1620 Connexins and Pannexins 1621 Cyclic nucleotide-regulated channels 1623 Epithelial sodium channels (ENaC) 1625 IP3 receptor 1626 Potassium channels 1630 Ryanodine receptor 1632 Sodium leak channel, non-selective 1633 Transient receptor potential channels 1643 Voltage-gated calcium channels 1645 Voltage-gated proton channel 1646 Voltage-gated sodium channels 1652 NUCLEAR HORMONE RECEPTORS 1654 1A. Thyroid Hormone Receptors 1655 1B. Retinoic acid receptors 1656 1C. Peroxisome proliferator-activated receptors 1657 1D. Rev-Erb receptors 1658 1F. Retinoic acid-related orphans 1659 1H. Liver X receptor-like receptors 1660 1I. Vitamin D receptor-like receptors 1661 2A. Hepatocyte nuclear factor-4 receptors 1662 2B. Retinoid X receptors 1663 2C. Testicular receptors 1664 2E. Tailless-like receptors 1665 2F. COUP-TF-like receptors 1666 3B. Estrogen-related receptors 1667 4A. Nerve growth factor IB-like receptors 1668 5A. Fushi tarazu F1-like receptors 1669 6A. Germ cell nuclear factor receptors 1670 0B. DAX-like receptors 1671 Steroid hormone receptors 1676 CATALYTIC RECEPTORS 1678 Cytokine receptor family 1684 GDNF receptor family 1685 Integrins 1688 Natriuretic peptide receptor family 1689 Pattern Recognition receptors 1692 Receptor serine/threonine kinase (RSTK) family 1695 Receptor tyrosine kinases 1702 Receptor tyrosine phosphatases (RTP) 1703 Tumour necrosis factor (TNF) receptor family 1706 TRANSPORTERS 1708 ATP-binding cassette transporter family 1712 F-type and V-type ATPases 1714 P-type ATPases 1717 SLC1 family of amino acid transporters 1719 SLC2 family of hexose and sugar alcohol transporters 1721 SLC3 and SLC7 families of heteromeric amino acid transporters (HATs) 1723 SLC4 family of bicarbonate transporters 1724 SLC5 family of sodium-dependent glucose transporters 1728 SLC6 neurotransmitter transporter family 1732 SLC8 family of sodium/calcium exchangers 1733 SLC9 family of sodium/hydrogen exchangers 1734 SLC10 family of sodium-bile acid co-transporters 1736 SLC11 family of proton-coupled metal ion transporters 1737 SLC12 family of cation-coupled chloride transporters 1739 SLC13 family of sodium-dependent sulphate/carboxylate transporters 1740 SLC14 family of facilitative urea transporters 1741 SLC15 family of peptide transporters 1742 SLC16 family of monocarboxylate transporters 1744 SLC17 phosphate and organic anion transporter family 1746 SLC18 family of vesicular amine transporters 1748 SLC19 family of vitamin transporters 1749 SLC20 family of sodium-dependent phosphate transporters 1750 SLC22 family of organic cation and anion transporters 1753 SLC23 family of ascorbic acid transporters 1754 SLC24 family of sodium/potassium/calcium exchangers 1755 SLC25 family of mitochondrial transporters 1760 SLC26 family of anion exchangers 1762 SLC27 family of fatty acid transporters 1763 SLC28 and SLC29 families of nucleoside transporters 1765 SLC30 zinc transporter family 1766 SLC31 family of copper transporters 1767 SLC32 vesicular inhibitory amino acid transporter 1768 SLC33 acetylCoA transporter 1769 SLC34 family of sodium phosphate co-transporters 1770 SLC35 family of nucleotide sugar transporters 1772 SLC36 family of proton-coupled amino acid transporters 1773 SLC37 family of phosphosugar/phosphate exchangers 1774 SLC38 family of sodium-dependent neutral amino acid transporters 1776 SLC39 family of metal ion transporters 1777 SLC40 iron transporter 1778 SLC41 family of divalent cation transporters 1779 SLC42 family of Rhesus glycoprotein ammonium transporters 1780 SLC43 family of large neutral amino acid transporters 1781 SLC44 choline transporter-like family 1782 SLC45 family of putative sugar transporters 1783 SLC46 family of folate transporters 1784 SLC47 family of multidrug and toxin extrusion transporters 1785 SLC48 heme transporter 1786 SLC49 family of FLVCR-related heme transporters 1787 SLC50 sugar transporter 1788 SLC51 family of steroid-derived molecule transporters 1789 SLC52 family of riboflavin transporters 1790 SLCO family of organic anion transporting polypeptides 1797 ENZYMES 1799 Acetylcholine turnover 1800 Adenosine turnover 1801 Amino acid hydroxylases 1802 L-Arginine turnover 1805 Carboxylases and decarboxylases 1807 Catecholamine turnover 1810 Ceramide turnover 1815 Cyclic nucleotide turnover 1820 Cytochrome P450 1824 Eicosanoid turnover 1828 Endocannabinoid turnover 1830 GABA turnover 1832 Glycerophospholipid turnover 1838 Haem oxygenase 1839 Hydrogen sulfide synthesis 1840 Inositol phosphate turnover 1842 Lanosterol biosynthesis pathway 1845 Peptidases and proteinases 1853 Protein serine/threonine kinases 1860 Sphingosine 1-phosphate turnover 1862 Thyroid hormone turnover

An Introduction to the Concise Guide to PHARMACOLOGY 2013/14

The great proliferation of drug targets in recent years has driven the need to provide a logically-organised synopsis of the nomenclature and pharmacology of these targets. This is the underlying reason for this Guide to PHARMACOLOGY 2013/14, distributed with the British Journal of Pharmacology, and produced in association with NC-IUPHAR, the Nomenclature Committees of the International Union of Basic and Clinical Pharmacology. Our intent is to produce an authoritative but user-friendly publication, which allows a rapid overview of the key properties of a wide range of established or potential pharmacological targets. The aim is to provide information succinctly, so that a newcomer to a particular target group can identify the main elements ‘at a glance’. It is not our goal to produce all-inclusive reviews of the targets presented; references to these are included in the Further Reading sections of the entries or, for many targets, the website www.guidetopharmacology.org provides access to more extensive information. The Guide to PHARMACOLOGY 2013/14 presents each entry, typically a circumscribed target class family on, wherever possible, a single page, so as to allow easy access and rapid oversight. The list of targets present is, in many cases, a comprehensive reflection of the known targets within the particular group. Our philosophy has been to present data on human proteins wherever possible, both in terms of structural information and pharmacology. To this end, the HGNC gene nomenclature and UniProt unique ID are indicated to allow rapid access through free online databases for further information. In a few cases, where structural or pharmacological information is not available for human targets, we have used data from other species, as indicated. A priority in constructing these tables was to present agents which represent the most selective and which are available by donation or from commercial sources, now or in the near future. The Guide is divided into seven further sections, which comprise pharmacological targets of similar structure/function. These are G protein-coupled receptors, ligand-gated ion channels, ion channels, catalytic receptors, nuclear hormone receptors, transporters and enzymes. In this overview are listed protein targets of pharmacological interest, which are not G protein-coupled receptors, ligand-gated ion channels, ion channels, nuclear hormone receptors, catalytic receptors, transporters or enzymes. In comparison with the Fifth Edition of the Guide to Receptors & Channels 1, we have added a number of new records, expanding the total to include over 2000 protein targets, primarily from increasing the content on transporters and enzymes. The Editors of the Guide have compiled the individual records, taking advice from many Collaborators (listed on page 1452). Where appropriate, an indication is given of the status of the nomenclature, as proposed by NC-IUPHAR, published in Pharmacological Reviews. Where this guidance is lacking, advice from several prominent, independent experts has generally been obtained to produce an authoritative consensus, which attempts to fit in within the general guidelines from NC-IUPHAR 2. Tabulated data provide ready comparison of selective agents and probes (radioligands and PET ligands, where available) within a family of targets and additional commentary highlights whether species differences or ligand metabolism are potential confounding factors. We recommend that any citations to information in the Concise Guide are presented in the following format: Alexander SPH et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14. Br J Pharmacol 170: 1449–1867.
NomenclatureAdipo1 receptorAdipo2 receptor
HGNC, UniProtADIPOR1, Q96A54ADIPOR2, Q86V24
Rank order of potencyglobular adiponectin > adiponectinglobular adiponectin adiponectin
Preferred abbreviationFABP1FABP2FABP3FABP4FABP5
Nomenclaturefatty acid binding protein 1, liverfatty acid binding protein 2, intestinalfatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)fatty acid binding protein 4, adipocytefatty acid binding protein 5 (psoriasis-associated)
HGNC, UniProtFABP1, P07148FABP2, P12104FABP3, P05413FABP4, P15090FABP5, Q01469
Rank order of potencystearic acid, oleic acid > palmitic acid, linoleic acid > arachidonic acid, α-linolenic acid 13stearic acid > palmitic acid, oleic acid > linoleic acid > arachidonic acid, α-linolenic acid 13stearic acid, oleic acid, palmitic acid > linoleic acid, α-linolenic acid, arachidonic acid 13oleic acid, palmitic acid, stearic acid, linoleic acid > α-linolenic acid, arachidonic acid 13–
CommentA broader substrate specificity than other FABPs, binding two fatty acids per protein 18Crystal structure of the rat FABP2 15Crystal structure of the human FABP3 19–Crystal structure of the human FABP5 11
Preferred abbreviationFABP6FABP7FABP8FABP9FABP12
Nomenclaturefatty acid binding protein 6, ilealfatty acid binding protein 7, brainperipheral myelin protein 2fatty acid binding protein 9, testisfatty acid binding protein 12
HGNC, UniProtFABP6, P51161FABP7, O15540PMP2, P02689FABP9, Q0Z7S8FABP12, A6NFH5
CommentAble to transport bile acids 20Crystal structure of the human FABP7 7In silico modelling suggests that FABP8 can bind both fatty acids and cholesterol 12––
Preferred abbreviationRBP1RBP2RBP3RBP4RBP5
Nomenclatureretinol binding protein 1, cellularretinol binding protein 2, cellularretinol binding protein 3, interstitialretinol binding protein 4, plasmaretinol binding protein 5, cellular
HGNC, UniProtRBP1, P09455RBP2, P50120RBP3, P10745RBP4, P02753RBP5, P82980
Rank order of potency–stearic acid > palmitic acid, oleic acid, linoleic acid, α-linolenic acid, arachidonic acid 14–––
Preferred abbreviationRBP7RLBP1CRABP1CRABP2
Nomenclatureretinol binding protein 7, cellularretinaldehyde binding protein 1cellular retinoic acid binding protein 1cellular retinoic acid binding protein 2
HGNC, UniProtRBP7, Q96R05RLBP1, P12271CRABP1, P29762CRABP2, P29373
Rank order of potency–11-cis-retinal, 11-cis-retinol > 9-cis-retinal, 13-cis-retinal, 13-cis-retinol, all-trans-retinal, retinol 8all-trans-retinoic acid > 9-cis-retinoic acid stearic acid > palmitic acid, oleic acid, linoleic acid, α-linolenic acid, arachidonic acid 14–
Nomenclatureσ1 (sigma non-opioid intracellular receptor 1)σ2
HGNC, UniProtSIGMAR1, Q99720–
Selective agonists(+)-SK&F10047, (RS)-PPCC (pKi 8.8) 25, PRE-084 (pIC50 7.4) 26PB-28 (pKi 8.3) 21
Selective antagonistsNE-100 (pIC50 8.4) 24, BD-1047 (pIC50 7.4) 23(RS)-SM21 (pIC50 7.2) 22
Radioligands (Kd)[3H]-pentazocine (Agonist)[3H]-di-o-tolylguanidine (Agonist)
  42 in total

Review 1.  Sigma receptors: potential medications development target for anti-cocaine agents.

Authors:  Rae R Matsumoto; Yun Liu; Megan Lerner; Eric W Howard; Daniel J Brackett
Journal:  Eur J Pharmacol       Date:  2003-05-23       Impact factor: 4.432

Review 2.  Adiponectin receptor binding proteins--recent advances in elucidating adiponectin signalling pathways.

Authors:  Christa Buechler; Josef Wanninger; Markus Neumeier
Journal:  FEBS Lett       Date:  2010-09-28       Impact factor: 4.124

3.  Classification of FABP isoforms and tissues based on quantitative evaluation of transcript levels of these isoforms in various rat tissues.

Authors:  Takenori Yamamoto; Atsushi Yamamoto; Masahiro Watanabe; Taisuke Matsuo; Naoshi Yamazaki; Masatoshi Kataoka; Hiroshi Terada; Yasuo Shinohara
Journal:  Biotechnol Lett       Date:  2009-06-30       Impact factor: 2.461

4.  The crystal structure of the liver fatty acid-binding protein. A complex with two bound oleates.

Authors:  J Thompson; N Winter; D Terwey; J Bratt; L Banaszak
Journal:  J Biol Chem       Date:  1997-03-14       Impact factor: 5.157

5.  Novel sigma receptor ligands: synthesis and biological profile.

Authors:  Orazio Prezzavento; Agata Campisi; Simone Ronsisvalle; Giovanni Li Volti; Agostino Marrazzo; Vincenzo Bramanti; Giuseppe Cannavò; Luca Vanella; Alfredo Cagnotto; Tiziana Mennini; Riccardo Ientile; Giuseppe Ronsisvalle
Journal:  J Med Chem       Date:  2007-02-13       Impact factor: 7.446

6.  Characterization of two novel sigma receptor ligands: antidystonic effects in rats suggest sigma receptor antagonism.

Authors:  R R Matsumoto; W D Bowen; M A Tom; V N Vo; D D Truong; B R De Costa
Journal:  Eur J Pharmacol       Date:  1995-07-14       Impact factor: 4.432

7.  Identification and characterization of a small molecule inhibitor of Fatty Acid binding proteins.

Authors:  Ann V Hertzel; Kristina Hellberg; Joseph M Reynolds; Andrew C Kruse; Brittany E Juhlmann; Anne J Smith; Mark A Sanders; Douglas H Ohlendorf; Jill Suttles; David A Bernlohr
Journal:  J Med Chem       Date:  2009-10-08       Impact factor: 7.446

Review 8.  Role of fatty acid binding proteins and long chain fatty acids in modulating nuclear receptors and gene transcription.

Authors:  Friedhelm Schroeder; Anca D Petrescu; Huan Huang; Barbara P Atshaves; Avery L McIntosh; Gregory G Martin; Heather A Hostetler; Aude Vespa; Danilo Landrock; Kerstin K Landrock; H Ross Payne; Ann B Kier
Journal:  Lipids       Date:  2007-09-19       Impact factor: 1.880

Review 9.  Adiponectin, an unlocking adipocytokine.

Authors:  Yiyi Sun; Keli Xun; Changguang Wang; Haiyu Zhao; Huichang Bi; Xiuping Chen; Yitao Wang
Journal:  Cardiovasc Ther       Date:  2009       Impact factor: 3.023

10.  Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2.

Authors:  Masato Furuhashi; Gürol Tuncman; Cem Z Görgün; Liza Makowski; Genichi Atsumi; Eric Vaillancourt; Keita Kono; Vladimir R Babaev; Sergio Fazio; MacRae F Linton; Richard Sulsky; Jeffrey A Robl; Rex A Parker; Gökhan S Hotamisligil
Journal:  Nature       Date:  2007-06-06       Impact factor: 49.962
View more
  122 in total

1.  The activation of supraspinal GPR40/FFA1 receptor signalling regulates the descending pain control system.

Authors:  K Nakamoto; T Nishinaka; N Sato; F Aizawa; T Yamashita; M Mankura; Y Koyama; F Kasuya; S Tokuyama
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

2.  Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding.

Authors:  Ting Song; Gaobo Chai; Yubo Liu; Xiaoyan Yu; Ziqian Wang; Zhichao Zhang
Journal:  Br J Pharmacol       Date:  2016-01-16       Impact factor: 8.739

Review 3.  Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities.

Authors:  Amos A Fatokun; Valina L Dawson; Ted M Dawson
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

4.  σ1 receptors activate astrocytes via p38 MAPK phosphorylation leading to the development of mechanical allodynia in a mouse model of neuropathic pain.

Authors:  J Y Moon; D H Roh; S Y Yoon; S R Choi; S G Kwon; H S Choi; S Y Kang; H J Han; A J Beitz; S B Oh; J H Lee
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

Review 5.  A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment.

Authors:  Jose M Palacios; Angel Pazos; Daniel Hoyer
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

6.  Highly selective CB2 receptor agonist A836339 has gastroprotective effect on experimentally induced gastric ulcers in mice.

Authors:  M Salaga; H Zatorski; M Zielińska; P Mosinska; J-P Timmermans; R Kordek; M Storr; J Fichna
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-07-14       Impact factor: 3.000

7.  Properties of human brain sodium channel α-subunits expressed in HEK293 cells and their modulation by carbamazepine, phenytoin and lamotrigine.

Authors:  Xin Qiao; Guangchun Sun; Jeffrey J Clare; Taco R Werkman; Wytse J Wadman
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

8.  Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.

Authors:  Isabelle Benz-de Bretagne; Noël Zahr; Amélie Le Gouge; Jean-Sébastien Hulot; Caroline Houillier; Khe Hoang-Xuan; Emmanuel Gyan; Séverine Lissandre; Sylvain Choquet; Chantal Le Guellec
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

9.  Functional Selectivity of CB2 Cannabinoid Receptor Ligands at a Canonical and Noncanonical Pathway.

Authors:  Amey Dhopeshwarkar; Ken Mackie
Journal:  J Pharmacol Exp Ther       Date:  2016-05-18       Impact factor: 4.030

10.  Peripheral interactions between cannabinoid and opioid systems contribute to the antinociceptive effect of crotalphine.

Authors:  F C Machado; V O Zambelli; A C O Fernandes; A S Heimann; Y Cury; G Picolo
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.